Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06832306 · ClinicalTrials.gov registry record · NA

STimulation to Activate RespIration

A NA study of ARDS (Moderate or Severe) and AHRF, sponsored by Lungpacer Medical.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
6
Study locations

NCT06832306 is a NA study of ARDS (Moderate or Severe) and AHRF that is actively recruiting participants, run by Lungpacer Medical. The registered enrollment target is 30 participants. The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06832306, a NA study of ARDS (Moderate or Severe) and AHRF, is actively recruiting participants, sponsored by Lungpacer Medical.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).

Interventions

  • DEVICE Phrenic Nerve Stimulation

Study Locations (6)

California

  • University of California San Diego - La Jolla

Louisiana

  • Louisiana State University Health Sciences - Shreveport

Ohio

  • Cleveland Clinic - Cleveland

Pennsylvania

  • Temple University - Philadelphia

South Carolina

  • Prisma Health - Columbia

Ontario

  • University Health Network (UHN) - Toronto

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-05-28
Est. Completion 2026-12
Phase NA

Sponsor

Lungpacer Medical

3 total trials

What the Registry Record Tells You About NCT06832306

The ClinicalTrials.gov registry entry for NCT06832306 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lungpacer Medical, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with ARDS (Moderate or Severe) appearing as the primary indexed condition, and to 1 intervention - of which Phrenic Nerve Stimulation is the first listed.

NCT06832306 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Louisiana, Ohio.

Frequently Asked Questions

What is clinical trial NCT06832306 about?

NCT06832306 is a clinical study titled "STimulation to Activate RespIration". Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphrag...

What is the current status of trial NCT06832306?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-05-28. Estimated completion is 2026-12.

What conditions does trial NCT06832306 study?

This clinical trial studies the following conditions: ARDS (Moderate or Severe), AHRF, Mechanically Ventilated ICU Patients.

What interventions are being tested in trial NCT06832306?

The interventions under investigation include: Phrenic Nerve Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06832306?

This trial is sponsored by Lungpacer Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06832306 being conducted?

This trial has 6 study locations across California, Louisiana, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.